公开(公告)号：US20160030543A1

公开(公告)日：2016-02-04

申请号：US14604620

申请日：2015-01-23

Applicant: PFIZER INC.

Inventor： Gary Warren Zlotnick ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark E. Ruppen ,  Annaliesa Sybil Anderson ,  John Erwin Farley ,  Liesel A. Bernfield

IPC: A61K39/095 ,  C07K14/22

CPC classification number: A61K39/095 ,  A61K2039/55577 ,  A61K2039/6018 ,  C07K14/22 ,  C07K16/1217

Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

公开(公告)号：US11472850B2

公开(公告)日：2022-10-18

申请号：US17060067

申请日：2020-09-30

Applicant: PFIZER INC.

Inventor： Annaliesa Sybil Anderson ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark Edward Ruppen

IPC: C07K14/22 ,  A61K39/095 ,  A61K39/00

Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.

公开(公告)号：US10829521B2

公开(公告)日：2020-11-10

申请号：US16713782

申请日：2019-12-13

Applicant: PFIZER INC.

Inventor： Annaliesa Sybil Anderson ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark Edward Ruppen

IPC: A61K39/095 ,  C07K14/22 ,  A61K39/00

Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.

公开(公告)号：US09561269B2

公开(公告)日：2017-02-07

申请号：US14604620

申请日：2015-01-23

Applicant: PFIZER INC.

Inventor： Gary Warren Zlotnick ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark E. Ruppen ,  Annaliesa Sybil Anderson ,  John Erwin Farley ,  Liesel A. Bernfield

IPC: A61K39/095 ,  C07K16/22 ,  C07K14/22 ,  C07K16/12 ,  A61K39/00

CPC classification number: A61K39/095 ,  A61K2039/55577 ,  A61K2039/6018 ,  C07K14/22 ,  C07K16/1217

Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.

Abstract translation: 一方面，本发明涉及包含与SEQ ID NO：71具有至少95％同一性的氨基酸序列的分离多肽。另一方面，本发明涉及免疫原性组合物，其包含分离的非脂化非 - 来自脑膜炎奈瑟氏球菌血清群B的丙酮酸化ORF2086多肽和来自脑膜炎球菌血清群的至少一种共轭荚膜糖。